Sunshine Act Fallout: Firms Worry About Whistleblower Suits, Reporting Details
Executive Summary
Authors are furious about publication expenditures firms have reported to CMS; companies continue to debate whether to report study drugs and are finding numerous errors on Open Payments website.
You may also be interested in...
Sunshine Website Goes Live With Some Context Sought By Industry
CMS releases data on $3.5 billion worth of payments made by drug and device companies to physicians and teaching hospitals in the last five months of 2013; an additional 199,000 payment records were not disclosed.
New York State To Conduct Its Own Review Of COVID-19 Vaccines In Another Blow To FDA’s Reputation
Governor Cuomo will establish two panels, one examining safety and efficacy and another considering distribution and pricing, to advise the state on how to approach use of coronavirus vaccines once one is approved.
Off-Label Use: US FDA Backs Away From ‘Totality Of Evidence’ Standard In Proposed Reg
New proposed rule says a manufacturer’s knowledge of the unapproved use of a product does not alone determine intended use. Former FDA lawyer says rule could set off fireworks over the scope of what the agency considers evidence of off-label use.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: